Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Jmk2454on Aug 02, 2019 3:44pm

37 Views

Post# 29990076

RE:RE:FEW FACTS

CNBC99 wrote: Kalytera Therapeutics, Inc. (OTCQB:KALTF) (KLY.V) has so far been a place where investors' money goes to die since it completed a reverse merger to list in Canada at the end of 2016. The stock price has decreased approximately 95% since Kalytera started trading and 90% since the start of 2018:

Penny - gave you the benefit of the doubt when you first posted as CNBC99 but you’ve deteriorated back to the old Penny. Just couldn’t keep it together could you. The multiple personalities are extremely disturbing.

Bullboard Posts

This junior mining stock offers billions in market exposure